Efficacy and safety of nivolumab plus ipilimumab (N plus I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up.

被引：7

作者：

Tannir, Nizar M.

Signoretti, Sabina

Choueiri, Toni K.

McDermott, David F.

Motzer, Robert J.

George, Saby

Powles, Thomas

Donskov, Frede

Tykodi, Scott S.

Pal, Sumanta K.

Gupta, Saurabh

Lee, Chung-Wei

McHenry, M. Brent

Rini, Brian I.

机构：

[1] UT MD Anderson Canc Ctr, Houston, TX USA

[2] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA USA

[3] Harvard Med Sch, Boston, MA 02115 USA

[4] Brigham & Womens Hosp, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA USA

[5] Beth Israel Deaconess Med Ctr, Dana Farber Harvard Canc Ctr, Boston, MA 02215 USA

[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[7] Roswell Pk Canc Inst, Buffalo, NY USA

[8] Queen Mary Univ London, Barts Canc Ctr, London, England

[9] Aarhus Univ Hosp, Aarhus, Denmark

[10] Univ Washington, Seattle, WA 98195 USA

[11] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[12] City Hope Natl Med Ctr, Duarte, CA USA

[13] Bristol Myers Squibb, Princeton, NJ USA

[14] Vanderbilt Univ, Med Ctr, Nashville, TN USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期

关键词：

D O I：

10.1200/JCO.2022.40.6_suppl.352

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

352

引用

页数：3

共 50 条

[41] Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): Subgroup analysis from the phase III JAVELIN renal 101 trial of first-line avelumab plus axitinib (A plus Ax) vs sunitinib (S)
Choueiri, T. K.
Larkin, J. M. G.
Pal, S. K.
Motzer, R. J.
Venugopal, B.
Alekseev, B. Y.
Miyake, H.
Gravis, G.
Bilen, M. A.
Chudnovsky, A.
Ching, K. A.
Mariani, M.
Robbins, P. B.
Huang, B.
di Pietro, A.
Albiges, L.
ANNALS OF ONCOLOGY, 2019, 30 : 361 - 361
[42] LIFETIME SURVIVAL ESTIMATES FOR NIVOLUMAB plus IPILIMUMAB AND SUNITINIB IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED/METASTATIC INTERMEDIATE- OR POOR (I/P)-RISK RENAL CELL CARCINOMA (1L ARCC) BASED ON 5-YEAR MINIMUM FOLLOW-UP DATA FROM CHECKMATE 214
Qendri, V
May, J. R.
Ejzykowicz, F.
Kurt, M.
Cakar, E.
Klijn, S.
VALUE IN HEALTH, 2022, 25 (01) : S24 - S24
[43] Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study
Choueiri, Toni K.
Eto, Masatoshi
Motzer, Robert
De Giorgi, Ugo
Buchler, Tomas
Basappa, Naveen S.
Mendez-Vidal, Maria Jose
Tjulandin, Sergei
Park, Se Hoon
Melichar, Bohuslav
Hutson, Thomas
Alemany, Carlos
McGregor, Bradley
Powles, Thomas
Gruenwald, Viktor
Alekseev, Boris
Rha, Sun Young
Kopyltsov, Evgeny
Kapoor, Anil
Gordoa, Teresa Alonso
Goh, Jeffrey C.
Staehler, Michael
Merchan, Jaime R.
Xie, Ran
Perini, Rodolfo F.
Mody, Kalgi
McKenzie, Jodi
Porta, Camillo
LANCET ONCOLOGY, 2023, 24 (03): : 228 - 238
[44] Association Between Depth of Response (DepOR) and Overall Survival (OS): Exploratory Analysis of Nivolumab plus Ipilimumab (N plus I) vs Sunitinib (S) in Patients with Previously Untreated Advanced Renal Cell Carcinoma (ARCC) in Checkmate 214
Gruenwald, Viktor
Choueiri, Toni K.
Rini, Brian I.
Powles, Thomas
George, Saby
Grimm, Marc-Oliver
Mchenry, M. Brent
Maurer, Matthew
Motzer, Robert J.
Hammers, Hans J.
Tannir, Nizar M.
Albiges, Laurence
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 74 - 75
[45] ASCO-GU: 2-Year Follow-up of the CheckMate-9ER Study: Sustained Treatment Benefit with First-line Therapy of advanced Renal Cell Carcinoma with Cabozantinib plus Nivolumab versus Sunitinib
不详
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (05)
[46] Patient-reported outcomes of patients with advanced renal cell carcinoma (aRCC) treated with first-line nivolumab plus cabozantinib versus sunitinib: The CheckMate 9ER trial.
Cella, David
Choueiri, Toni K.
Blum, Steven, I
Ejzykowicz, Flavia
Hamilton, Melissa
Zhang, Joshua
Ivanescu, Cristina
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[47] Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial
Tykodi, Scott S.
Gordan, Lucio N.
Alter, Robert S.
Arrowsmith, Edward
Harrison, Michael R.
Percent, Ivor
Singal, Rakesh
Van Veldhuizen, Peter
George, Daniel J.
Hutson, Thomas
Zhang, Joshua
Zoco, Jesus
Johansen, Jennifer L.
Kalebasty, Arash Rezazadeh
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (02)
[48] Nivolumab plus cabozantinib (N plus C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial.
Apolo, Andrea B.
Powles, Thomas
Burotto, Mauricio
Bourlon, Maria Teresa
Hsieh, James J.
Basso, Umberto
Shah, Amishi Yogesh
Suarez, Cristina
Porta, Camillo
Barrios, Carlos H.
Gurney, Howard
Kessler, Elizabeth R.
Retz, Margitta
George, Saby
Escudier, Bernard
Zhang, Joshua
Simsek, Burcin
Scheffold, Christian
Motzer, Robert J.
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[49] Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial
Cella, David
Motzer, Robert J.
Suarez, Cristina
Blum, Steven, I
Ejzykowicz, Flavia
Hamilton, Melissa
Wallace, Joel F.
Simsek, Burcin
Zhang, Joshua
Ivanescu, Cristina
Apolo, Andrea B.
Choueiri, Toni K.
LANCET ONCOLOGY, 2022, 23 (02): : 292 - 303
[50] Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.
Rini, Brian I.
Plimack, Elizabeth R.
Stus, Viktor
Gafanov, Rustem
Waddell, Tom
Nosov, Dmitry
Pouliot, Frederic
Alekseev, Boris
Soulieres, Denis
Melichar, Bohuslav
Vynnychenko, Ihor O.
Azevedo, Sergio Jobim
Borchiellini, Delphine
McDermott, Raymond S.
Bedke, Jens
Tamada, Satoshi
Wu, Sterling
Burgents, Joseph
Molife, L. Rhoda
Powles, Thomas
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA4501 - LBA4501

← 1 2 3 4 5 →